---
company: Neuronetics, Inc.
ticker: STIM
form: 8-K
filed: 2026-11-04
accepted: 2026-11-04T12:55:08+00:00
accession: 0001193125-26-446239
source: https://www.sec.gov/Archives/edgar/data/1227636/000119312526446239/
quarterly_report: https://www.sec.gov/Archives/edgar/data/1227636/000110465926122380/
---

# Neuronetics (STIM) Q3 2026 earnings

## Header

- Company: Neuronetics, Inc.
- Reported: 2026-11-04 07:55 BMO ET
- Source: 8-K only — accession 0001193125-26-446239, Item 2.02 + Exhibit 99.1
- Verdict: Revenue and gross margin expanded, and operating income turned positive, driven by Greenbrook growth and improved margins.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $41.96M | +12.5% | +0.8% | Ex. 99.1, income statement |
| EPS (GAAP) | -$0.02 | +0.11 | +0.03 | Ex. 99.1, income statement |
| Net income | -$1.69M | +$7.35M | +$0.19M | Ex. 99.1, income statement |
| Adj. EBITDA | $1.89M | +$6.57M | +$1.59M | Ex. 99.1, income statement |
| Adj. EBITDA margin | 4.5% | +10.2 pp | +1.2 pp | Ex. 99.1, income statement |

## Revenue breakdown

| Segment | Actual | YoY | Share of revenue | Note |
|---|---:|---:|---:|---|
| NeuroStar revenue | $15.77M | +1.8% | 37.6% | — |
| Greenbrook revenue | $26.19M | +20.1% | 62.4% | Record quarter |

## Margins and costs

- Gross margin: 52.2% (prior 45.9%, change +6.3 pp)
- Operating expenses: $21.35M (+12.4% YoY)
- One-offs in the quarter: Restructuring $0.56M; Loss on extinguishment of debt $0
- Effective tax rate: not stated in the 8-K
- Non-GAAP bridge: Adds back stock-based compensation, loss on extinguishment of debt, and restructuring; these add-backs recur.

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---:|---|
| Total cash | $27.90M | $25.00M | $34.10M | +$2.90M YoY |
| Weighted average shares | 77.00M | 73.13M | 67.31M | +9.4% YoY |

## Guidance

| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Operating Expense Guidance | Not provided in this release | Not provided in this release | — |

## What drove it

- Revenue story: Greenbrook revenue grew 20.1% YoY to $26.19M, while NeuroStar revenue grew 1.8% YoY to $15.77M.
- EPS story: EPS improved due to lower net loss, driven by higher revenue, improved gross margins, and lower operating expenses.
- One-off check: Restructuring $0.56M and loss on extinguishment of debt $0 (non-recurring).

## The good

- Greenbrook revenue reached a record $26.19M
- Adjusted EBITDA turned positive at $1.89M
- Gross margin expanded to 52.2%

## The bad

- Net loss remains at $1.69M
- NeuroStar revenue grew only 1.8% YoY

## The ugly

- none

## Open questions

- What is the specific operating expense guidance for FY 2026?
- What is the expected impact of the new psychedelics offering on revenue?

## Full release

### Neuronetics (STIM) earnings release, November 4, 2026

Neuronetics, Inc. (STIM) · Form 8-K, Item 2.02 · Filed 2026-11-04 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1227636/000119312526446239/)

Neuronetics Reports Third Quarter 2026 Financial and Operating Results

MALVERN, PA., November 4, 2026 – Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar®

TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced its financial and operating results for the third quarter of 2026.

Third Quarter 2026 Highlights

Recent Operational Highlights

“This quarter showed our strategy taking hold across our business. We delivered a record third quarter within Greenbrook as well as NeuroStar system sales. This reflects both our revenue cycle management advances as well as the positive reception of our expanded NeuroStar go-to-market options. We also continued to demonstrate our prioritization on profitability and cashflow generation,” said Dan Reuvers, President and Chief Executive Officer of Neuronetics. “We’re continuing to focus on new and expanded partnerships for NeuroStar, serving more patients in our Greenbrook clinics and preparing for the introduction of an even more comprehensive offering with the introduction of psychedelics.”

Third Quarter 2026 Financial and Operating Results for the Three Months Ended September 30, 2026

Total revenue for the three months ended September 30, 2026, was $42.0 million, an increase of $4.7 million, or

12.5%, compared to the three months ended September 30, 2025, of $37.3 million. The increase was primarily driven by higher Greenbrook revenue, which increased to $26.2 million in the third quarter of 2026 from $21.8 million in the third quarter of 2025, reflecting continued growth of the Greenbrook business.

Gross margin increased from 45.9% for the three months ended September 30, 2025, to 52.2% for the three months ended September 30, 2026. The increase in gross margin was primarily driven by the positive impact of our new go-to-market strategy, as well as improved revenue cycle management within the Greenbrook clinics.

Operating expenses during the third quarter of 2026 were $21.3 million, a decrease of

$3.1 million, or 13%, compared to $24.4 million in the third quarter of 2025, primarily attributable to lower sales and marketing expenses, partially offset by higher general and administrative expenses.

Income from operations during the third quarter of 2026 was $0.5 million, an increase of $7.9 million, as compared to a loss of $7.3 million in the third quarter of 2025. Adjusted EBITDA during the third quarter of 2026 was $1.9 million, an increase of $6.6 million compared to a loss of $4.7 million in the third quarter of 2025.

Net loss attributable to Neuronetics stockholders for the third quarter of 2026 was $1.7 million, or $0.02 per share, as compared to $9.0 million, or $0.13 per share, for the third quarter of 2025. Net loss per share was based on 77,003,536 and 67,308,607 weighted average common shares outstanding for the third quarters of 2026 and 2025, respectively.

As of September 30, 2026, the Company held $27.9 million in total cash, consisting of cash and cash equivalents of $22.1 million and

$5.8 million of restricted cash, compared to total cash of $34.1 million as of December 31, 2025.

Submitted 510(k) application for

Accelerated TMS

The Company submitted a 510(k) to the FDA for an accelerated TMS protocol in August, which is currently under review. Pending approval, this has the potential to expand access to TMS for more patients, as condensed protocols can be more advantageous for some patients.

Entered agreement with Wave Neuro to pursue treatment of PTSD pending 510(k) submission

Wave Neuroscience, Inc. (“Wave Neuro”) has a proprietary software algorithm that leverages electroencephalogram (“EEG”) data to enable TMS to treat post-traumatic stress disorder (“PTSD”). The Company has signed a distribution agreement with Wave Neuro and plans to seek FDA clearance to add NeuroStar as a TMS system compatible with Wave Neuro’s PTSD indication. This clearance would allow NeuroStar customers to treat PTSD on their existing systems using Wave Neuro’s software algorithm.

NeuroStar Launched First-Ever TMS Integration with EHR/EMR Platform

The Company announced the integration of its TrakStar® practice management platform with

AdvancedMD’s electronic health/medical record (“EHR/EMR”), practice management, and revenue cycle platform. The first-of-its-kind integration connects TMS treatment data with clinical documentation, scheduling, and billing workflows, helping reduce duplicate work and administrative burden for providers. The integration is expected to become available to existing NeuroStar providers using AdvancedMD in the fourth quarter of 2026, with broader availability for providers adopting the platform going forward.

Business Outlook

For the full year 2026, Neuronetics now expects:

Operating Expense Guidance: FY 2026

The following table presents the Company’s reconciliation between Operating Expenses and Operating Expenses less

Non-cash

Stock-Based Compensation. This adjusted guidance is based on assumptions that management believes are reasonable under the circumstances. However, they are not necessarily indicative of the

Company’s future performance. Operating Expenses less Stock Based Compensation are projected Operating Expenses for the fiscal year 2026, less non-cash stock-based compensation.

Webcast and Conference Call Information

The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/7ri4xna9. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.

About Neuronetics

Neuronetics, Inc. is a leader in... (truncated)ining innovative treatment technologies with direct patient care. Through its NeuroStar Advanced Therapy system, the Company is a leading provider of transcranial magnetic stimulation (“TMS”) treatment and, through Greenbrook TMS Inc. (“Greenbrook”), operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped.

NeuroStar Advanced Therapy is the leading TMS treatment for major depressive disorder (“MDD”) in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with

MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged

15-21.

For safety information and indications for use, visit

NeuroStar.com.

“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995:

Certain statements in this press release, including the documents incorporated by reference herein, include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,”

“plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,”

“predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions. These statements include those relating to the Company’s business outlook and current expectations for upcoming quarters and fiscal year 2026, including with respect to revenue, expenses, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties, and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products and services; developments in respect of competing technologies and therapies for the indications that our products and services treat; product defects; our ability to obtain and maintain intellectual property protection for our technology; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; potential effects of evolving and/or extensive government regulation; the terms of our credit facility; our self-sustainability; existing cash balance; our ability to achieve positive cash flows; and our ability to continue as a going concern. For a discussion of these and other related risks, please refer to the Company’s recent filings with the U.S. Securities and Exchange

Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov, including, without limitation, the factors described under the heading “Risk Factors” in Neuronetics’ Annual Report on Form

10-K for the fiscal year ended December 31, 2025 and the Company’s Quarterly Report on Form

10-Q for the quarter ended March 31, 2026, as may be updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the

Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations.

Investor Contact:

Aman Patel or Mark Klausner

ICR Healthcare

443-213-0499 ir@neuronetics.com

Media Contact:

EvolveMKD

646-517-4220

NeuroStar@evolvemkd.com

NEURONETICS, INC.

Consolidated Statements of Operations

(Unaudited; In thousands, except per share data)

NEURONETICS, INC.

Consolidated Balance Sheets

(Unaudited; In thousands, except per share data)

NEURONETICS, INC.

Consolidated Statements of Cash Flows

(Unaudited; In thousands)

Non-GAAP

Financial Measures (Unaudited)

EBITDA and Adjusted EBITDA are not measures of financial performance under generally accepted accounting principles in the U.S. (“GAAP”), and should not be construed as a substitute for, or superior to, GAAP net loss. However, management uses both the GAAP and non-GAAP financial measures internally to evaluate and manage the Company’s operations and to better understand its business. Further, management believes that the addition of the non-GAAP financial measures provides meaningful supplementary information to, and facilitates analysis by, investors in evaluating the Company’s financial performance, results of operations and trends. The Company’s calculation of EBITDA and Adjusted EBITDA may not be comparable to similarly designated measures reported by other companies, because companies and investors may differ as to what type of events warrant adjustment.

The following table reconciles reported net loss to

EBITDA and Adjusted EBITDA:

Footnotes

References

1 The effectiveness of SPRAVATO in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO. For more important safety information about SPRAVATO, please visit spravatohcp.com.

#### Financial statements

##### Income Statement (Revenues by Segments Three Months Ended September 30, — Third Quarter 2026 Financial and Operating Results for the Three Months Ended September 30, 2026 (Unaudited; in thousands, except percentages))

| | Revenues by Segments Three Months Ended September 30, – 2026 – Amount – (Unaudited; in thousands, except percentages) | Revenues by Segments Three Months Ended September 30, – 2025 – Amount – (Unaudited; in thousands, except percentages) | % Change – (Unaudited; in thousands, except percentages) |
|---|---:|---:|---:|
| NeuroStar revenue | 15,770 | 15,489 | 1.8% |
| Greenbrook revenue | 26,192 | 21,808 | 20.1% |
| Total revenues | 41,962 | 37,297 | 12.5% |

##### Income Statement (Three Months Ended September 30, — (Unaudited; In thousands, except per share data))

| | Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| **Revenues** | | | | |
| NeuroStar | 15,770 | 15,489 | 43,372 | 43,889 |
| Greenbrook | 26,192 | 21,808 | 74,612 | 63,491 |
| Total revenues | 41,962 | 37,297 | 117,984 | 107,380 |
| **Cost of revenues** | | | | |
| NeuroStar | 3,610 | 4,607 | 9,780 | 12,068 |
| Greenbrook | 16,462 | 15,582 | 48,937 | 44,708 |
| Total cost of revenues | 20,072 | 20,189 | 58,717 | 56,776 |
| Gross profit | 21,890 | 17,108 | 59,267 | 50,604 |
| **Operating expenses:** | | | | |
| Sales and marketing | 8,484 | 11,848 | 29,205 | 35,715 |
| General and administrative | 11,675 | 11,077 | 36,127 | 36,364 |
| Research and development | 1,190 | 1,504 | 3,890 | 4,918 |
| Total operating expenses | 21,349 | 24,429 | 69,222 | 76,997 |
| Income (Loss) from operations | 541 | -7,321 | -9,955 | -26,393 |
| **Other (income) expense:** | | | | |
| Interest expense | 2,144 | 2,206 | 6,535 | 6,097 |
| Loss on extinguishment of debt |  |  | 539 |  |
| Other income, net | -47 | -126 | -1,229 | -561 |
| Net loss | -1,556 | -9,401 | -15,800 | -31,929 |
| Less: Net gain (loss) attributable to non-controlling interest | 136 | -356 | 121 | -89 |
| Net loss attributable to Neuronetics stockholders | -1,692 | -9,045 | -15,921 | -31,840 |
| Net loss per share of common stock outstanding, basic and diluted attributable to Neuronetics stockholders | -0.02 | -0.13 | -0.22 | -0.49 |
| Weighted average common shares outstanding, basic and diluted | 77,004 | 67,309 | 73,268 | 65,006 |

##### Income Statement (Three Months ended September 30, — The following table reconciles reported net loss to EBITDA and Adjusted EBITDA: (in thousands))

| | Three Months ended September 30, – 2026 | Three Months ended September 30, – 2025 | Nine months ended September 30, – 2026 | Nine months ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| Net loss attributable to Neuronetics stockholders’ | -1,692 | -9,045 | -15,921 | -31,840 |
| Interest expense, net | 2,097 | 2,080 | 5,306 | 5,536 |
| Depreciation and amortization | 742 | 886 | 2,216 | 2,698 |
| EBITDA | 1,147 | -6,079 | -8,399 | -23,606 |
| Stock based compensation (Note 1) | 178 | 1,409 | 2,543 | 4,667 |
| Loss on extinguishment of debt (Note 2) |  |  | 539 |  |
| Restructuring (Note 3) | 562 |  | 875 |  |
| Adjusted EBITDA | 1,887 | -4,670 | -4,442 | -18,939 |

##### Balance Sheet (September 30, 2026 — (Unaudited; In thousands, except per share data))

| | September 30, 2026 | December 31, 2025 |
|---|---:|---:|
| **Current assets:** | | |
| Cash and cash equivalents | 22,106 | 28,134 |
| Restricted cash and cash equivalents | 5,750 | 6,000 |
| Accounts receivable, net of allowance for credit losses of $563 and $1,043 as of September 30, 2026 and December 31, 2025, respectively | 14,435 | 16,469 |
| Inventory | 4,943 | 4,327 |
| Current portion of net investments in sales-type leases | 250 | 225 |
| Current portion of prepaid commission expense | 2,652 | 3,050 |
| Current portion of notes receivable | 258 | 424 |
| Prepaid expenses and other current assets | 3,494 | 2,922 |
| Total current assets | 53,888 | 61,551 |
| Property and equipment, net | 3,182 | 4,466 |
| Goodwill | 23,622 | 23,622 |
| Intangible assets, net | 17,056 | 18,149 |
| Operating lease right-of-use assets | 24,694 | 23,560 |
| Net investments in sales-type leases | 87 | 98 |
| Prepaid commission expense | 6,376 | 7,972 |
| Long-term notes receivable | 24 | 151 |
| Other assets | 3,029 | 1,982 |
| Total assets | 131,958 | 141,551 |
| **Current liabilities:** | | |
| Accounts payable | 9,963 | 10,739 |
| Accrued expenses | 10,354 | 12,316 |
| Current portion of deferred revenue | 997 | 753 |
| Deferred and contingent consideration | 250 | 500 |
| Other payables | 254 | 652 |
| Current portion of operating lease liabilities | 5,038 | 5,561 |
| Total current liabilities | 26,856 | 30,521 |
| Long-term debt, net | 61,752 | 65,807 |
| Deferred revenue | 10 | 48 |
| Operating lease liabilities | 20,937 | 18,935 |
| Total liabilities | 109,555 | 115,311 |
| **Equity:** | | |
| Common stock, $0.01 par value: 250,000 shares authorized; 77,728 and 68,994 shares issued and outstanding on September 30, 2026 and December 31, 2025, respectively | 777 | 690 |
| Additional paid-in capital | 492,774 | 480,475 |
| Accumulated deficit | -474,843 | -458,787 |
| Total Stockholders’ equity | 18,708 | 22,378 |
| Non-controlling interest | 3,695 | 3,862 |
| Total equity | 22,403 | 26,240 |
| Total liabilities and equity | 131,958 | 141,551 |

##### Cash Flow (From the 10-Q · Nine Months Ended September 30, — The following table sets forth a summary of our cash flows for the nine months ended September 30, 2026 and 2025: (in thousands))

| | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|
| Net Cash used in Operating activities | -9,191 | -21,282 |
| Net Cash used in Investing activities | -1,059 | -585 |
| Net Cash provided by Financing activities | 3,972 | 36,879 |
| Net increase (decrease) in Cash, Cash equivalents and Restricted cash | -6,278 | 15,012 |
